Literature DB >> 3878129

Pharmacokinetics and bactericidal activity of cefuroxime axetil.

C M Ginsburg, G H McCracken, M Petruska, K Olson.   

Abstract

The pharmacokinetics of cefuroxime axetil were studied in 10 adult volunteers aged 24 to 31 years (mean age, 27), 22 infants and children aged 11 to 68 months (mean age, 33 months), and 11 children aged 7 years, 7 months to 12 years, 3 months (mean age, 11 years, 1 month). Mean peak plasma concentrations of cefuroxime occurred between 90 and 120 min in all study patients and were independent of the fasting or feeding status. The areas under the concentration-time curves were significantly higher in adult volunteers who received cefuroxime axetil with milk than in those who received the drug while fasting or with applesauce. The bioavailability of cefuroxime axetil was significantly enhanced in children by the concomitant ingestion of cefuroxime axetil and infant formula or whole milk. The areas under the concentration-time curves were 25 to 88% higher when cefuroxime axetil and milk were administered simultaneously than when the same dose was given to all fasting patients. The plasma bactericidal activities of cefuroxime against beta-lactamase-positive and -negative strains of Haemophilus influenzae and Staphylococcus aureus at the time of peak plasma concentrations were independent of feeding status and were similar in adults and in children. Against these strains, 52% of the children and 38% of the adults had peak bactericidal levels of 1:8 or greater.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3878129      PMCID: PMC180292          DOI: 10.1128/AAC.28.4.504

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.

Authors:  S M Harding; P E Williams; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

2.  The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food.

Authors:  P E Williams; S M Harding
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

3.  Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing.

Authors:  D K Sommers; M Van Wyk; P E Williams; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability.

Authors:  G H McCracken; C M Ginsburg; J C Clahsen; M L Thomas
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

5.  Pharmacokinetics of cephradine suspension infants and children.

Authors:  C M Ginsburg; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

  5 in total
  17 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Killing kinetics of five orally administered antibiotics at clinically achievable concentrations against Moraxella catarrhalis.

Authors:  E Bingen; F Bourgeois; H Chardon; C Doit; N Lambert-Zechovsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

Review 3.  Pharmacokinetics and tissue concentrations of cefuroxime.

Authors:  T B Vree; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

4.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 5.  The future of new oral antibiotics including the quinolones.

Authors:  M G Bergeron
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

Review 6.  Applying Pharmacodynamics and Antimicrobial Stewardship to Pediatric Preseptal and Orbital Cellulitis.

Authors:  Grant T Stimes; Jennifer E Girotto
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

Review 7.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

8.  Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.

Authors:  Michael E Pichichero; Gary V Doern; Joseph L Kuti; David P Nicolau
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

10.  The relationship of diastereomer hydrolysis kinetics to shelf-life predictions for cefuroxime axetil.

Authors:  N A Nguyen
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.